Updated just now · Live
Stock analysis, price data, and AI-powered insights for Tempus AI Inc (TEM).
Tempus AI Inc operates in the Life Sciences Tools & Services sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for TEM.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). TEM Stock Intelligence Report. [stoxpulse.com/stocks/tem]
Disclaimer: The information on this page about Tempus AI Inc (TEM) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Tempus AI Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Tempus to Report First Quarter 2026 Financial Resu...
6h ago
Could Tempus AI’s GenoPredicta Data Push Quietly R...
5d ago
StoxPulse AI results for TEM: Pulse Score 57/100. Primary sentiment trends from 14 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$10.19B
P/E Ratio
—
EPS
$-0.46
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Sector
Life Sciences Tools & Services
Industry
Life Sciences Tools & Services
Website
investors.tempus.com/Tempus to Report First Quarter 2026 Financial Results on May 5
Could Tempus AI’s GenoPredicta Data Push Quietly Reshape Its Precision Oncology Edge (TEM)?
Tempus AI (TEM) Unveils Cancer Test Kit, Soars 13.9%
Tech Leads, Dow Lags As Oil Holds Near $92: What's Moving Markets Wednesday?
Tempus AI Stock Jumps 10% After Predicta Collaboration Expansion
Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring
Tempus AI shares are trading higher after the company announced a commercial expansion with Predicta Biosciences of a co-branded whole-genome sequencing assay intended for the comprehensive genomic characterization of hematologic malignancies and measurable residual disease monitoring.
Tempus AI, Inc. And Predicta Biosciences Announce Collaboration To Expand Life Sciences Access To Ultrasensitive Whole-Genome Sequencing Assay For Hematologic Malignancies And MRD Monitoring